请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo/CP-547632/1/200810
产品编号:200810
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo/CP-547632/1/200810
商品介绍

CP-547632

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:200810

CAS#:252003-65-9

Description:CP-547632, also known as PAN-90806,is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor , and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM. After oral administration of CP-547,632 to mice bearing NIH3T3/H-ras tumors, VEGFR-2 phosphorylation in tumors was inhibited in a dose-dependent fashion (EC50 590 ng/ml). CP-547,632 is a well-tolerated, orally-bioavailable inhibitor presently under clinical investigation for the treatment of human malignancies.

Price and Availability

SizePriceShipping out timeQuantity
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

CP-547632 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200810Name: CP-547632CAS#: 252003-65-9Chemical Formula: C20H24BrF2N5O3SExact Mass: 531.07513Molecular Weight: 532.4Elemental Analysis:C, 45.12; H, 4.54; Br, 15.01; F, 7.14; N, 13.15; O, 9.02; S, 6.02

Synonym:CP547632; CP 547632; CP-547632; PAN90806; PAN 90806; PAN-90806; CP632; OSI632; CP 632; OSI 632; CP-632; OSI-632

IUPAC/Chemical Name:3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide

InChi Key:HXHAJRMTJXHJJZ-UHFFFAOYSA-N

InChi Code:InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30)

SMILES Code:O=C(C1=C(NC(NCCCCN2CCCC2)=O)SN=C1OCC3=C(F)C=C(Br)C=C3F)N

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Phase I/II trial results:   Seventy patients were enrolled and 68 patients were treated, 37 in phase 1 and 31 in phase 2 (14 with the combination and 17 with chemotherapy alone). Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention. CP-547,632 did not significantly affect the pharmacologic profiles of paclitaxel and carboplatin. No subject had CR. In phase I, seven subjects (22.6%) had a confirmed partial response. In phase II, four subjects (28.6%) receiving CP-547,632 plus chemotherapy had a confirmed partial response. In the phase II chemotherapy alone group, four subjects (25%) had a confirmed partial response. CONCLUSION:  The combination of CP-547,632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily. Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash. CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer. (source: Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9. Epub 2006 Oct 10.).   

References

1: Cohen RB, Langer CJ, Simon GR, Eisenberg PD,Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, HealeyD. A phase I/randomized phase II, non-comparative, multicenter, openlabel trial of CP-547,632 in combination with paclitaxel and carboplatinor paclitaxel and carboplatin alone as first-line treatment for advancednon-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2007Jun;60(1):81-9. Epub 2006 Oct 10. PubMed PMID: 17031646.

2: Wakelee HA, Schiller JH. Targeting angiogenesis with vascularendothelial growth factor receptor small-molecule inhibitors: novelagents with potential in lung cancer. Clin Lung Cancer. 2005 Sep;7 Suppl1:S31-8. Review. PubMed PMID: 16159417.

3: Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, EmersonE, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S,Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA,Schaeffer T, Whalen PM, Roberts WG. Pharmacological characterization ofCP-547,632, a novel vascular endothelial growth factor receptor-2tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003 Nov1;63(21):7301-9. PubMed PMID: 14612527.

4: Sridhar SS, Shepherd FA. Targeting angiogenesis: a review ofangiogenesis inhibitors in the treatment of lung cancer. Lung Cancer.2003 Dec;42 Suppl 1:S81-91. Review. PubMed PMID: 14611919.

5: Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for thetreatment of lung cancer. Lung Cancer. 2003 Aug;41 Suppl 1:S63-72.Review. PubMed PMID: 12867064.  

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔